Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15214

    +

    P3.01-005 - Clinical Effects of Icotinib for Brain Metastasis in Chinese Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation (ID 2484)

    09:30 - 09:30  |  Author(s): L. Deng
    • Abstract
    • Slides

    Background:
    Icotinib hydrochloride, an oral EGFR tyrosine kinase inhibitor, was proved to be non-inferior to gefitinib in patients with non-small-cell lung cancer (NSCLC). Brain metastasis is a serious factor associated with poor outcomes of NSCLC because systemic chemotherapy usually showed little effects due to the blood-brain barrier. Besides, other treatments such as whole brain or stereotatic radiotherapy may cause neurological complications. There have been some studies showing that gefitinib or erlotinib plus concurrent brain radiotherapy or not was effective in controlling brain metastasis in NSCLC. Herein, we observed the function of Icotinib on brain metastasis in Chinese NSCLC patients harboring an EGFR mutation.
    
    Methods:
    The clinical data of 28 NSCLC patients with brain metastasis referred to Qingdao Municipal Hospital from May 2012 to December 2014 were retrospectively analyzed. All the patients had pathological diagnosis of adenocarcinoma. EGFR mutation state was confirmed by ARMS PCR or Sanger sequencing. The patients received first line Icotinib of 125mg three times a day after giving informed consent and they would continue to take Icotinib unless disease progressed or other reasons. No concurrent brain radiotherapy was given during this process.
    
    Results:
    Out of the 28 patients treated, 12 achieve partial response, 11 experienced stable disease and 5 experienced progressive disease. The response rate and disease control rate of Icotinib for brain metastasis was 42.8% and 82.1% respectively. After a median follow-up of 15.1 months (range 5-27 months), the median progression-free time was 7.5 months. Rash and diarrhea were the most common adverse events.
    
    Conclusion:
    Icotinib might be an alterative treatment for brain metastasis in Chinese NSCLC patients harboring an activating EGFR mutation.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.